Insights in the regulation of trimetylamine N-oxide production using a comparative biomimetic approach suggest a metabolic switch in hibernating bearsShow others and affiliations
2020 (English)In: Scientific Reports, E-ISSN 2045-2322, Vol. 10, no 1, article id 20323Article in journal (Refereed) Published
Abstract [en]
Experimental studies suggest involvement of trimethylamine N-oxide (TMAO) in the aetiology of cardiometabolic diseases and chronic kidney disease (CKD), in part via metabolism of ingested food. Using a comparative biomimetic approach, we have investigated circulating levels of the gut metabolites betaine, choline, and TMAO in human CKD, across animal species as well as during hibernation in two animal species. Betaine, choline, and TMAO levels were associated with renal function in humans and differed significantly across animal species. Free-ranging brown bears showed a distinct regulation pattern with an increase in betaine (422%) and choline (18%) levels during hibernation, but exhibited undetectable levels of TMAO. Free-ranging brown bears had higher betaine, lower choline, and undetectable TMAO levels compared to captive brown bears. Endogenously produced betaine may protect bears and garden dormice during the vulnerable hibernating period. Carnivorous eating habits are linked to TMAO levels in the animal kingdom. Captivity may alter the microbiota and cause a subsequent increase of TMAO production. Since free-ranging bears seems to turn on a metabolic switch that shunts choline to generate betaine instead of TMAO, characterisation and understanding of such an adaptive switch could hold clues for novel treatment options in burden of lifestyle diseases, such as CKD.
Place, publisher, year, edition, pages
Nature Publishing Group, 2020. Vol. 10, no 1, article id 20323
National Category
Behavioral Sciences Biology
Identifiers
URN: urn:nbn:se:oru:diva-87594DOI: 10.1038/s41598-020-76346-1ISI: 000595844700008PubMedID: 33230252Scopus ID: 2-s2.0-85096444876OAI: oai:DiVA.org:oru-87594DiVA, id: diva2:1503798
Funder
The Karolinska Institutet's Research FoundationNovo NordiskAstraZenecaSwedish Heart Lung Foundation, 20160384
Note
Funding Agencies:
Njurfonden (Swedish Kidney Foundation)
Strategic Research Programme in Diabetes at Karolinska Institutet (Swedish Research Council) 2009-1068
University of Glasgow
Constant Pharma Ltd
4D Pharma limited
Lundbeckfonden R126-2012-12408 R194-2015-1108 R286-2018-367
Augustinus Foundation
2020-11-252020-11-252024-01-16Bibliographically approved